Share-based Payment Arrangement, Expense of Cartesian Therapeutics, Inc. from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cartesian Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • Cartesian Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,590,000, a 53% increase year-over-year.
  • Cartesian Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $10,242,000, a 54% decline year-over-year.
  • Cartesian Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,582,000, a 74% decline from 2023.
  • Cartesian Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25,778,000, a 130% increase from 2022.
  • Cartesian Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11,194,000, a 45% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cartesian Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,242,000 $2,590,000 +$895,000 +53% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $9,347,000 $3,279,000 +$1,688,000 +106% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $7,659,000 $2,508,000 +$1,077,000 +75% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $6,582,000 $1,865,000 -$15,533,000 -89% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $22,115,000 $1,695,000 -$626,000 -27% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $22,741,000 $1,591,000 -$2,192,000 -58% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $24,933,000 $1,431,000 -$845,000 -37% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $25,778,000 $17,398,000 +$15,122,000 +664% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $10,656,000 $2,321,000 -$280,000 -11% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $10,936,000 $3,783,000 +$219,000 +6.1% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $10,717,000 $2,276,000 -$477,000 -17% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $11,194,000 $2,276,000 +$23,000 +1% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $11,171,000 $2,601,000 +$697,000 +37% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $10,474,000 $3,564,000 +$1,781,000 +100% 01 Apr 2022 30 Jun 2022 10-Q 17 Aug 2023 2023 Q2
Q1 2022 $8,693,000 $2,753,000 +$973,000 +55% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $7,720,000 $2,253,000 +$1,017,000 +82% 01 Oct 2021 31 Dec 2021 10-K 07 Mar 2024 2023 FY
Q3 2021 $6,703,000 $1,904,000 +$608,000 +47% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $6,095,000 $1,783,000 +$302,000 +20% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $5,793,000 $1,780,000 +$371,000 +26% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $5,422,000 $1,236,000 -$191,000 -13% 01 Oct 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
Q3 2020 $5,613,000 $1,296,000 -$7,000 -0.54% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $5,620,000 $1,481,000 +$230,000 +18% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $5,390,000 $1,409,000 +$229,000 +19% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $5,161,000 $1,427,000 -$363,000 -20% 01 Oct 2019 31 Dec 2019 10-K 10 Mar 2022 2021 FY
Q3 2019 $5,524,000 $1,303,000 -$182,000 -12% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $5,706,000 $1,251,000 -$35,000 -2.7% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $5,741,000 $1,180,000 +$27,000 +2.3% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $5,714,000 $1,790,000 +$579,000 +48% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2021 2020 FY
Q3 2018 $5,135,000 $1,485,000 +$171,000 +13% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $4,964,000 $1,286,000 +$423,000 +49% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $4,541,000 $1,153,000 +$460,000 +66% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $4,081,000 $1,211,000 +$442,000 +57% 01 Oct 2017 31 Dec 2017 10-K 15 Mar 2019 2018 Q4
Q3 2017 $3,639,000 $1,314,000 +$681,000 +108% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $2,958,000 $863,000 +$496,000 +135% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $2,462,000 $693,000 +$411,000 +146% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $2,051,000 $769,000 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2019 2018 Q4
Q3 2016 $633,000 +$381,000 +151% 01 Jul 2016 30 Sep 2016 10-Q 10 Nov 2016 2016 Q3
Q2 2016 $367,000 +$52,000 +17% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2016 2016 Q2
Q1 2016 $282,000 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
Q3 2015 $252,000 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $315,000 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2

Cartesian Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,582,000 -$19,196,000 -74% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $25,778,000 +$14,584,000 +130% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $11,194,000 +$3,474,000 +45% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $7,720,000 +$2,298,000 +42% 01 Jan 2021 31 Dec 2021 10-K 07 Mar 2024 2023 FY
2020 $5,422,000 +$261,000 +5.1% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 $5,161,000 -$553,000 -9.7% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022 2021 FY
2018 $5,714,000 +$1,633,000 +40% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2021 2020 FY
2017 $4,081,000 +$2,030,000 +99% 01 Jan 2017 31 Dec 2017 10-K 15 Mar 2019 2018 Q4
2016 $2,051,000 +$926,000 +82% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2019 2018 Q4
2015 $1,125,000 -$99,000 -8.1% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2018 2017 Q4
2014 $1,224,000 01 Jan 2014 31 Dec 2014 10-K 28 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.